FAQ/Help |
Calendar |
Search |
Today's Posts |
|
![]() |
#1 | |||
|
||||
Grand Magnate
|
We talked about this exciting drug opportunity in the following thread:
http://neurotalk.psychcentral.com/thread52769.html ... but the latest news is that it looks like it is getting fast-tracked for drug approval in the US: Multiple Sclerosis drug dirucotide (MBP8298) receives fast track designation from FDA BioMS Medical Corp. announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients. Fast track designation is an FDA status reserved for products that are intended to treat a serious or life-threatening condition and that demonstrate the potential to address unmet medical needs for that condition. Fast track designation can potentially facilitate development and expedite the review process. "Our receipt of fast track designation for dirucotide in the U.S. is a significant milestone for both BioMS Medical and the MS community," said Kevin Giese, President and CEO of BioMS Medical. "Based on previous clinical results, we believe dirucotide is well-positioned to become a first-in-class treatment for secondary progressive MS patients, a large patient population with very limited treatment options." Source: BioMS Medical Corp. (04/09/08) http://www.msrc.co.uk/index.cfm?fuse...ow&pageid=1308 Cherie
__________________
I am not a Neurologist, Physician, Nurse, or Hairdresser ... but I have learned that it is not such a great idea to give oneself a haircut after three margaritas
. |
|||
![]() |
![]() |
"Thanks for this!" says: | barb02 (09-11-2008), dmplaura (09-04-2008), ewizabeth (09-04-2008), Ivy2 (09-04-2008), Jules A (09-06-2008), MSacorn (09-08-2008), NurseNancy (09-10-2008), sheena (09-15-2008), tovaxin_lab_rat (09-04-2008), Twinkletoes (09-04-2008), weeble (09-04-2008) |
![]() |
#2 | |||
|
||||
Magnate
|
Wow, that is exciting and good news!
I linked that to my friend who's mother is SPMS and bed ridden. I'm sure he'll be very happy to read this news. ![]()
__________________
2004 to present - Trigeminal Neuralgia 2007 to present - Burning Mouth Syndrome March 2008 - Multiple Sclerosis DX 05/2008 - Relapse 05/2008 to 02/2009 - Copaxone 10/2011 - Relapse - Optic Neuritis developed 9/2012 - Relapse - Balance issues 1 sided 8/2012 - Erythema Nodosum - diagnosed 10/2012, reaction to Topiramate (Topamax) April 7/14 - Raynaud's Syndrome DX |
|||
![]() |
![]() |
![]() |
#3 | |||
|
||||
Junior Member
|
While I believe this is possibly really good news, but this is another treatment to slow progression, not to repair damage. It is a glimmer of hope for SPMS and possibly others. I've heard it described as/ compared to "super Copaxone".
__________________
. This Too Shall Pass . |
|||
![]() |
![]() |
"Thanks for this!" says: | dmplaura (09-05-2008) |
![]() |
#4 | |||
|
||||
Member
|
I posted this on the other thread on this drug too.
Here is some more information on dirucotide (somewhat from a business perspective). Published one month ago. http://www.forbes.com/business/forbe.../0901/062.html
__________________
On Tysabri and love it. . |
|||
![]() |
![]() |
![]() |
#5 | ||
|
|||
New Member
|
Is anyone participating in the trials? How are you feeling?
|
||
![]() |
![]() |
![]() |
#6 | ||
|
|||
Member
|
Theyve got to come up with a better name for it. Maybe we can start a contest?
|
||
![]() |
![]() |
Reply |
|
|
![]() |
||||
Thread | Forum | |||
Duodopa...Solvay Receives Fast Track Designation From FDA - L-Dopa Intestinal Gel | Parkinson's Disease Clinical Trials | |||
Duodopa®, Solvay Pharmaceuticals, Inc. Receives Fast Track Designation From U.S. FDA | Parkinson's Disease | |||
Fast Track designation for Levodopa/Carbidopa Intestinal Gel | Parkinson's Disease | |||
Knopp Neurosciences Receives Orphan Designation For KNS-760704 For Treatment Of ALS | ALS News & Research |